Physician profile
Hector L Dicarlo
NPI 1356597785
$9,676.40
in general payments reported to CMS, 2019-2025
39 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $1,328 · 2021: $2,618 · 2022: $929 · 2023: $452 · 2024: $2,140 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.00 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,968.00 | 2019-2022 | |
| Parapro, LLC | $1,000.00 | 2024 | Natroba |
| Astrazeneca Pharmaceuticals Lp | $646.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $537.38 | 2019-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $488.71 | 2019-2024 | |
| Pfizer INC. | $435.40 | 2019-2024 | |
| Lilly USA, LLC | $342.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $300.75 | 2021-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $279.19 | 2020-2023 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.82 | 2021-2024 | Jardiance, Synjardy |
| Esperion Therapeutics, INC. | $268.92 | 2020-2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $244.03 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.36 | 2019-2025 | Xifaxan |
| Allergan, INC. | $209.25 | 2019-2020 | |
| Biotronik INC. | $195.90 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Dicarlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.